rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2008-4-1-87-90rpcardio-1070Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯWHAT CAN WE EXPECT USING ACE INHIBITOR RAMIPRIL IN PERSONS WITH HIGH CARDIOVASCULAR RISK AND EARLY DISORDERS OF CARBOHYDRATE METABOLISM? LESSONS OF DREAM TRIALНА ЧТО МОЖНО РАССЧИТЫВАТЬ ПРИ ИСПОЛЬЗОВАНИИ ИНГИБИТОРА АПФ РАМИПРИЛА У ЛИЦ С ВЫСОКИМ СЕРДЕЧНО-СОСУДИСТЫМ РИСКОМ И РАННИМИ НАРУШЕНИЯМИ УГЛЕВОДНОГО ОБМЕНА: УРОКИ ИССЛЕДОВАНИЯ DREAMМамедовМ. Н.MamedovM. N.СтроеваМ. В.StroevaM. B.Государственный научно-исследовательский центр профилактической медицины Росмедтехнологий, МоскваРоссияState Research Center of Preventive Medicine of Rosmedtechnology, MoscowRussian Federation200825012016418790Copyright © Mamedov M.N., Stroeva M.B., 20162016Мамедов М.Н., Строева М.В.Mamedov M.N., Stroeva M.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/1070

Primary prevention of diabetes in persons with high cardiovascular risk is an actual problem. Results of DREAM trial are discussed. Influence of ACE inhibitor, ramipril, on risk of diabetes onset in patients with pre-diabetes and low cardiovascular risk is focused. Metabolic effects of other groups of antihypertensive drugs and their ability to prevent diabetes onset are compared. Ramipril three years therapy resulted in normalization in glucose level but did not have effect on frequency of diabetes onset. Change in life-style and regular usage of ACE inhibitor, ramipril, can contribute in normalization of glycemia level in patients with combination of pre-diabetes and arterial hypertension.

Обсуждаются результаты исследования DREAM, а именно – влияние ингибитора АПФ рамиприла на риск развития сахарного диабета у лиц с преддиабетом и низким сердечно-сосудистым риском. Также сравниваются метаболические эффекты других групп антигипертензивных препаратов и их способность предотвращать развитие сахарного диабета. Применение рамиприла на протяжении трех лет способствовало значимому снижению уровня глюкозы до нормогликемии, однако не влияло на число новых случаев диабета. При сочетании преддиабета с артериальной гипертонией изменение образа жизни и систематическое применение ингибитора АПФ рамиприла способствуют нормализации гликемии.

сахарный диабетсердечно-сосудистый рискрамиприлdiabetescardiovascular riskramiprilReferencesОганов Р.Г. Концепция факторов риска как основа профилактики сердечно-сосудистых заболеваний. Врач 2001;(7):3-6Оганов Р.Г. Концепция факторов риска как основа профилактики сердечно-сосудистых заболеваний. Врач 2001;(7):3-6Оганов Р.Г., Мамедов М.Н., редакторы. Школа по диагностике и лечению метаболического синдрома. Пособие для врачей. М.: Медицинская книга; 2007.Оганов Р.Г., Мамедов М.Н., редакторы. Школа по диагностике и лечению метаболического синдрома. Пособие для врачей. М.: Медицинская книга; 2007.Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26(11): 3160-7Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26(11): 3160-7Bartnik M, Ryden L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25(21):1880-90.Bartnik M, Ryden L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25(21):1880-90.Мамедов М.Н. Опыт комбинированной антигипертензивной терапии у больных с метаболическим синдромом. Росс кардиол журн 2006;(4):69-74Мамедов М.Н. Опыт комбинированной антигипертензивной терапии у больных с метаболическим синдромом. Росс кардиол журн 2006;(4):69-74Padwal R, Majumdar SR, Johnson JA, et al. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 2005;28(3):736-44.Padwal R, Majumdar SR, Johnson JA, et al. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 2005;28(3):736-44.Nilsson P., Cifkova R., Kjeldsen S. Mancia G. Prevention of the 2 diabetes mellitus. J Hypertens 2006;24(12):2478-82.Nilsson P., Cifkova R., Kjeldsen S. Mancia G. Prevention of the 2 diabetes mellitus. J Hypertens 2006;24(12):2478-82.Williams B. Recent hypertension trials. Implications and controversies. J Am Coll Cardiol 2005;45(6):813-27.Williams B. Recent hypertension trials. Implications and controversies. J Am Coll Cardiol 2005;45(6):813-27.Valensi P. All in one. Monde Moderne (France) 2004: 71-110, 184- 209.Valensi P. All in one. Monde Moderne (France) 2004: 71-110, 184- 209.Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-convertingenzyme inhibitor, ramipil, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342(3):145-53.Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-convertingenzyme inhibitor, ramipil, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342(3):145-53.Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103(7):919-25.Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103(7):919-25.Kaplan NM. The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin Ther 1996; 18(4): 658-670Kaplan NM. The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin Ther 1996; 18(4): 658-670Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355(9200):253-9Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355(9200):253-9Marre M, Lievre M, Chatellier G, et al; DIABHYCAR Study Investigators. Effects of low dose ramipril on the cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomized, double blind, placebo controlled trial (The DLABHYCAR study). BMJ 2004;328:495.Marre M, Lievre M, Chatellier G, et al; DIABHYCAR Study Investigators. Effects of low dose ramipril on the cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomized, double blind, placebo controlled trial (The DLABHYCAR study). BMJ 2004;328:495.Ingelfinger JR, Solomon CG. Angiotensin-converting-enzyme inhibitors for impaired glucose tolerance--is there still hope? N Engl J Med 2006;355(15):1608-10Ingelfinger JR, Solomon CG. Angiotensin-converting-enzyme inhibitors for impaired glucose tolerance--is there still hope? N Engl J Med 2006;355(15):1608-10The DREAM trial investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355(15):1551-62The DREAM trial investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355(15):1551-62The DECODE study group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetologia 1999; 42: 647-54The DECODE study group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetologia 1999; 42: 647-54Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program research group. Reduction in the incidence of the type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6):393-403Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program research group. Reduction in the incidence of the type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6):393-403Tuomilehto J, Lindström J, Eriksson JG, et al.; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344(18):1343-50Tuomilehto J, Lindström J, Eriksson JG, et al.; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344(18):1343-50

The authors declare that there are no conflicts of interest present.